Models of multiple system atrophy.

Area of Science:

• Neuroscience
• Neuropathology
• Genetics

Background:

• Multiple system atrophy (MSA) is a fatal, adult-onset neurodegenerative disease characterized by autonomic failure, parkinsonism, and ataxia.
• MSA is an α-synucleinopathy, sharing pathological features with Parkinson's disease and dementia with Lewy bodies, specifically abnormal α-synuclein inclusions.
• The primary pathological hallmark in MSA is glial cytoplasmic inclusions (GCIs) composed of α-synuclein within oligodendroglial cells, leading to significant neuronal loss.

Purpose of the Study:

• To provide an overview of Multiple System Atrophy (MSA), an atypical Parkinson's syndrome.
• To summarize the available animal models for MSA.
• To discuss the relevance of these models for preclinical testing of disease-modifying therapies.

Main Methods:

• Review of existing literature on MSA and its animal models.
• Categorization of rodent models into neurotoxin-based and transgenic approaches.
• Analysis of the utility of these models for evaluating therapeutic strategies.

Main Results:

• Two main types of rodent models exist: neurotoxin-based models targeting neuronal loss and transgenic models overexpressing α-synuclein in oligodendroglia to replicate GCI pathology.
• These models aim to mimic key neuropathological features of MSA, including neuronal degeneration and the formation of GCIs.
• The models vary in their ability to replicate the full spectrum of MSA pathology.

Conclusions:

• Animal models are crucial for understanding MSA pathogenesis and developing effective treatments due to the limited understanding of disease mechanisms.
• Both neurotoxin-based and transgenic models offer valuable insights but have limitations in fully recapitulating MSA.
• Current MSA models are essential for preclinical testing of novel therapeutic interventions aimed at disease modification.